Dr George Vassiliou is a Reader in Haematological Malignancies at the University of Cambridge and a Cancer Research UK Senior Fellow. He is a member of Faculty at the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute, and practices as a Consultant Haematologist at Cambridge University Hospitals, where he treats patients with haematological cancers.
His group studies the pre-clinical evolution, pathogenesis and treatment of acute myeloid leukaemia (AML), a disease with a survival below 30% and for which treatments have not changed significantly for more than 25 years. They develop and study bespoke mouse models to investigate how particular gene mutations drive AML and related cancers and were one of the groups that described the phenomenon of clonal haematopoiesis (CH), believed to be the precursor of myeloid and other haematological malignancies. More recently, the group and their collaborators showed that individuals at high risk of AML can be identified years in advance through the characteristic of their CH clones. Furthermore, they have pioneered a CRIPSR-Cas9 genome-wide screening platform for the identification of genetic vulnerabilities of cancer cells and used this to identify novel therapeutic targets in AML, including the RNA methyltransferase METTL3 and the splicing gene SRPK1.